Maridebart Cafraglutide

6 trials 2 recruiting

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

2 Recruiting

4 Completed trials

1 Sponsors

18 Countries

Phase III

Phase II

Phase III: 4 Phase II: 2

Oversight events:

1 corrective measure across 1 trial

View oversight register →

Indications tested

Obesity 3 Overweight 3 Type 2 diabetes mellitus 1 Obstructive sleep apnoea syndrome 1

Sponsors using this IMP

All trials

6 total

Maridebart Cafraglutide versus Placebo in Adult Participants with Obstructive Sleep Apnea on Positive Airway Pressure Therapy (MARITIME-OSA-… Recruiting

2025-522703-14-00 Phase III 6 countries Amgen Inc.
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Phase III 18 countries Amgen Inc.
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARIT… Ended

2024-515523-11-00 Phase III 6 countries Amgen Inc.
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MA… Ended

2024-515524-36-00 Phase III 8 countries Amgen Inc.
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Subjects With Type 2 Diabetes Mell… Ended

2024-513539-25-00 Phase II 8 countries Amgen Inc.
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Witho… Ended

2023-510470-13-00 Phase II 5 countries Amgen Inc.

Showing 1–6 of 6 trials

← All drugs A–Z